BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27
• 29
• 30
• 31

• 

  Neurodegenerative disease

  UniQure Clears Path to Accelerated Approval for Huntington’s Gene Therapy

  In a Type B meeting, the FDA signified that it will allow uniQure to use a natural history control, the composite Unified Huntington’s Disease Rating Scale, and neurofilament light chain levels to support the accelerated approval of its gene therapy AMT-130.

  December 10, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Cancer

  GSK Touts 42% Survival Benefit for Blenrep in Multiple Myeloma, Strengthening Bid for Market Return

  The overall survival edge over J&J’s Darzalex will help GSK strengthen its case as it plots the market comeback of Blenrep, which was pulled after a failed confirmatory study.

  December 10, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Cancer

  Lilly’s Strong Phase III Survival Data for Jaypirca Clouded by Deaths

  According to Jake Van Naarden, president of Lilly Oncology, the excess deaths could be due to the high rate of crossover in BRUIN CLL-321.

  December 10, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Layoffs

  Carisma Therapeutics to Cut 34% of Staff, Reprioritize Pipeline

  Carisma’s second workforce reduction this year likely leaves the company with 44 full-time employees as turns its focus to developing therapies for fibrosis, oncology and autoimmune diseases.

  December 10, 2024

   · 

  2 min read

   · 

  Angela Gabriel
• 

  CAR-T

  Gilead/Arcellx’s Anito-Cel’s Differentiated Safety Profile Challenges J&J/Legend’s Carvykti

  Anito-cel has shown no signs of delayed neurotoxicity at around 9 months of follow-up, hinting at a safety profile that could set it apart from J&J and Legend’s Carvykti.

  December 10, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer

  December 10, 2024

   · 

  7 min read
• Press Releases

  Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium

  December 10, 2024

   · 

  5 min read
• Press Releases

  Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus

  December 10, 2024

   · 

  11 min read
• Press Releases

  Longest Follow-Up Data Reported for Kite’s Tecartus® CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits

  December 10, 2024

   · 

  19 min read
• Press Releases

  Ichnos Glenmark Innovation (IGI) Presents First Clinical Data from Phase 1 Study of Trispecific TREAT™ Antibody, ISB 2001, Showing High Overall Response Rate (ORR) with Durable Responses and Favorable Safety Profile in Patients with Heavily Pretreated Multiple Myeloma

  December 10, 2024

   · 

  6 min read